Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance ... of Disease Study BMI Collaborators analysis published in The Lancet this March ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

After years of researching the finance industry, Simons realized the untapped potential of employing quantitative analysis ... on the stock. During a call with an analyst, Novo Nordisk stated ...

Our analysis is essentially based on how sell-side ... between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Novo Nordisk is expected to post ...

Our analysis is essentially based ... in earnings estimate revisions and short-term stock price movements. For the current quarter, Novo Nordisk is expected to post earnings of $0.91 per share ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cuts its guidance for the year. For the full year, the company now expects sales growth ...